Early JW Therapeutics Backer Ruins Regulatory Breakthrough Party With Stake Sale 传来重大利好，药明巨诺却遭淡马锡抛弃？
The Chinese cancer drug maker’s shares surged on news of approval for its core product, only to return to earth after early investor Temasek exited 这家manbetx3.0
抗癌药制造商的股价因其核心产品获得批准而大涨，但在早期投资者淡马锡退出后又股价回落。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.